Patents by Inventor Julia C. Watson
Julia C. Watson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7432047Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: October 4, 2006Date of Patent: October 7, 2008Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 7285383Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: August 1, 2005Date of Patent: October 23, 2007Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 7045284Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: June 14, 2004Date of Patent: May 16, 2006Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Publication number: 20040254140Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: ApplicationFiled: June 14, 2004Publication date: December 16, 2004Applicant: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6824976Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: November 28, 2000Date of Patent: November 30, 2004Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6777179Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: March 27, 2002Date of Patent: August 17, 2004Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6667152Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: March 22, 2002Date of Patent: December 23, 2003Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6623961Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: March 28, 2002Date of Patent: September 23, 2003Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Publication number: 20030144226Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: ApplicationFiled: March 27, 2002Publication date: July 31, 2003Applicant: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6579674Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: March 28, 2002Date of Patent: June 17, 2003Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Publication number: 20020165194Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: ApplicationFiled: March 28, 2002Publication date: November 7, 2002Applicant: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Publication number: 20020160977Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: ApplicationFiled: March 28, 2002Publication date: October 31, 2002Applicant: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Publication number: 20020160976Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: ApplicationFiled: March 22, 2002Publication date: October 31, 2002Applicant: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6156496Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: September 8, 1997Date of Patent: December 5, 2000Assignee: Ribogene, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 5998159Abstract: The present invention provides methods for identification of antibiotic agents which cause the accumulation of ppGpp in bacterial organisms involving a relA-independent pathway. The methods comprise screening assays in which test compounds are brought into contact with relA.sup.- test cells and observing the effect such compounds have on ppGpp levels in the test cells. The invention also provides genetically manipulated relA.sup.- test cells which contain a reporter gene the expression of which is sensitive to the level of ppGpp. The invention also encompasses agents identified by the screening assays, and uses of these agents in the treatment of infectious diseases.Type: GrantFiled: February 10, 1998Date of Patent: December 7, 1999Assignee: RiboGene, Inc.Inventors: Julia C. Watson, Charles M. Moehle, Ritu Gina Bahador, Victor James Hernandez